Longeveron (NASDAQ:LGVN) Given “Buy” Rating at HC Wainwright

Longeveron (NASDAQ:LGVN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 392.61% from the company’s current price.

Separately, Maxim Group reduced their price objective on shares of Longeveron from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 27th.

Longeveron Stock Down 2.9 %

NASDAQ LGVN opened at $2.03 on Monday. The company’s 50 day moving average is $2.03 and its 200-day moving average is $2.10. Longeveron has a 12-month low of $0.77 and a 12-month high of $23.90. The firm has a market cap of $29.15 million, a P/E ratio of -0.23 and a beta of 0.36.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.80). The firm had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $0.53 million. Longeveron had a negative net margin of 1,513.83% and a negative return on equity of 237.57%. Equities analysts expect that Longeveron will post -3.89 EPS for the current year.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. Renaissance Technologies LLC purchased a new position in Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned approximately 2.31% of Longeveron at the end of the most recent reporting period. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.